| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014933792 |
| P356 | DOI | 10.1186/S12885-016-2633-2 |
| P3181 | OpenCitations bibliographic resource ID | 4136079 |
| P932 | PMC publication ID | 4972997 |
| P698 | PubMed publication ID | 27488675 |
| P50 | author | Marjolijn van Keep | Q96212178 |
| P2093 | author name string | Dawn Lee | |
| Divyagiri Seshagiri | |||
| Kerry Gairy | |||
| Pushpike Thilakarathne | |||
| P2860 | cites work | Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma | Q22306235 |
| Mantle cell lymphoma: evolving management strategies | Q26862390 | ||
| A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma | Q28254924 | ||
| Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Q28286064 | ||
| Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study | Q30826621 | ||
| Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma | Q33420889 | ||
| Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches | Q33586239 | ||
| Treatment of older patients with mantle-cell lymphoma. | Q34641279 | ||
| Mantle cell lymphoma: established therapeutic options and future directions | Q35605571 | ||
| Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network | Q35677959 | ||
| Current treatment approaches for mantle-cell lymphoma | Q36254655 | ||
| Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network | Q38047385 | ||
| Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival | Q43899637 | ||
| ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. | Q45124918 | ||
| Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res | Q45236772 | ||
| Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy | Q46586190 | ||
| Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. | Q53259278 | ||
| The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Models Due to Differing Patient Weights. | Q54479883 | ||
| Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q57217007 | ||
| Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007 | Q83227525 | ||
| Mantle cell lymphoma | Q84320340 | ||
| Guidelines for the investigation and management of mantle cell lymphoma | Q85004110 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| mantle cell lymphoma | Q268713 | ||
| rituximab | Q412323 | ||
| P304 | page(s) | 598 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma | |
| P478 | volume | 16 |
Search more.